OX40 Antibody Sequence Optimization for T Cell Proliferation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective treatments based on OX40, particularly anti-OX40 antibodies that offer improved binding capabilities and manufacturing yields, to address immune-related diseases and cancer by enhancing effector T cell function and inhibiting regulatory T cell suppression.
Innovation Solution
Development of fully human anti-OX40 IgG class antibodies with modified heavy and light chain sequences that exhibit enhanced binding affinity and agonist activity, including Fab and single-chain antibody fragments, to specifically target OX40 and induce T cell proliferation and cytokine production while inhibiting regulatory T cell function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild type anti-OX40 antibodies are used, then manufacturing is simpler, but binding affinity and agonist activity are insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid sequences in the antibody's heavy and light chains. Specific substitutions (e.g., L31P, L92E in heavy chain; L25E, L89P in light chain) were made to optimize binding affinity and agonist activity while maintaining manufacturability
Solution Approach 2:
The patent applies local quality by making targeted modifications at specific positions within the antibody sequence rather than global changes. The modifications are concentrated in the variable regions (VH and VL domains) where they directly impact antigen binding, while leaving other regions unchanged to maintain simplicity
2Reliability
If antibody sequences are modified to enhance binding, then binding affinity improves, but manufacturing yield decreases
Solution Approach 1:
The patent optimized parameters by testing multiple sequence variants and selecting those that achieve the best balance between binding affinity (Kd values) and expression yield. The final sequences were chosen to provide enhanced binding without excessive complexity that would hinder manufacturing
Solution Approach 2:
The patent replaced the mechanical/physical constraint of complex folding and assembly requirements with sequence modifications that maintain structural simplicity. The modifications were designed to improve binding through altered molecular interactions rather than through complex structural rearrangements that would complicate manufacturing
3Productivity
If wild type antibodies are used, then manufacturing yield is higher, but ability to stimulate T cell proliferation and inhibit Treg function is insufficient
Solution Approach 1:
The patent changed amino acid parameters in the antibody sequences to enhance agonist activity. Specific substitutions were made to improve the ability to stimulate effector T cell proliferation and inhibit regulatory T cell function, while selecting variants that maintained adequate expression levels
Solution Approach 2:
The patent created a dynamic optimization process where multiple antibody variants were generated and tested to find the optimal balance between manufacturing yield and biological activity. The selected sequences represent a dynamic equilibrium point where both parameters are satisfied
Data Source
AI summary
The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.